{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:59:16Z","timestamp":1790189956645,"version":"4.1.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"37","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,12]]},"abstract":"<jats:p>This study aimed to evaluate the clinical efficacy of Fuzi Lizhong Decoction (FZLZD) as an adjunct therapy for advanced gastric cancer (GC) when combined with the capecitabine plus oxaliplatin (XELOX) plus sintilimab regimen and to elucidate its potential therapeutic mechanisms through network pharmacology. Network pharmacology was employed to identify active ingredients of FZLZD and predict key targets and signaling pathways involved in GC treatment. GeneMANIA-based Functional Association analysis, core microRNA screening, and immunohistochemical analysis of core proteins were performed. Molecular docking was used to verify the direct regulatory effects of these traditional Chinese medicine monomers on the targets. FZLZD was found to have 732 targets associated with GC, involving processes such as protein phosphorylation, signal transduction, and gene transcription regulation. These targets were enriched in tumor- and metabolism-related pathways. The core proteins included protein tyrosine phosphatase non-receptor type 1, estrogen receptor 2, cytochrome P450 family 19 subfamily A member 1, and interleukin 6, while the core drug monomers included glypallichalcone, \u03b1-amyrin, deoxyharringtonine, and neokadsuranic acid B. Molecular docking results showed strong binding between the core targets and monomers. Clinical comparative studies have shown that compared with the XELOX plus sintilimab regimen alone, the combination of FZLZD and this regimen can significantly reduce traditional Chinese medicine symptom scores, lower tumor marker levels, and interleukin 6 levels in the treatment of advanced GC, and meaningfully improve health-related quality of life metrics. This study provides preliminary evidence that FZLZD, when combined with the XELOX plus sintilimab regimen, enhances the efficacy of the treatment for advanced GC. The results suggest that FZLZD may modulate key targets and signaling pathways, offering insights for further research and clinical application.<\/jats:p>","DOI":"10.1097\/md.0000000000044262","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T21:00:57Z","timestamp":1757970057000},"page":"e44262","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Network pharmacology analysis and clinical efficacy study of Fuzi Lizhong Decoction combined with XELOX plus sintilimab in the treatment of advanced gastric cancer"],"prefix":"10.1097","volume":"104","author":[{"given":"Wei","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Oncology, The Fourth Clinical Medical College of Xinjiang Medical University, Urumqi, Xinjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Oncology, College of Health Medicine, Three Gorges University, Yichang, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxing","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Oncology, Yichang Central People\u2019s Hospital, Yichang, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weipeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Yichang Central People\u2019s Hospital, Yichang, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lirong","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Three Gorges University Hospital of Traditional Chinese Medicine & Yichang Hospital of Traditional Chinese Medicine, Yichang, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Three Gorges University Hospital of Traditional Chinese Medicine & Yichang Hospital of Traditional Chinese Medicine, Yichang, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hushuang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Three Gorges University Hospital of Traditional Chinese Medicine & Yichang Hospital of Traditional Chinese Medicine, Yichang, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingying","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Oncology, College of Health Medicine, Three Gorges University, Yichang, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siying","family":"Le","sequence":"additional","affiliation":[{"name":"Department of Oncology, College of Health Medicine, Three Gorges University, Yichang, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5045-6376","authenticated-orcid":false,"given":"Hongliang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hospital of Traditional Chinese Medicine Affiliated to Xinjiang Medical University, Urumqi, Xinjiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260923","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/978-1-60327-492-0_23","article-title":"Epidemiology of stomach cancer.","volume":"472","author":"Brenner","year":"2009","journal-title":"Methods Mol Biol"},{"key":"R2-20260923","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R3-20260923","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/jgh.15037","article-title":"Gastric cancer prevention strategies: a global perspective.","volume":"35","author":"Eusebi","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"R4-20260923","doi-asserted-by":"crossref","first-page":"632168","DOI":"10.3389\/fonc.2021.632168","article-title":"Efficacy and safety of astragalus-containing traditional Chinese medicine combined with platinum-based chemotherapy in advanced gastric cancer: a systematic review and meta-analysis.","volume":"11","author":"Cheng","year":"2021","journal-title":"Front Oncol"},{"key":"R5-20260923","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3389\/fphar.2020.00132","article-title":"Meta-analysis of paclitaxel-based chemotherapy combined with traditional Chinese medicines for gastric cancer treatment.","volume":"11","author":"Li","year":"2020","journal-title":"Front Pharmacol"},{"key":"R6-20260923","doi-asserted-by":"crossref","first-page":"1405704","DOI":"10.3389\/fmed.2024.1405704","article-title":"Risk factor analysis and nomogram construction of postoperative complications for patients with locally advanced gastric cancer who received neoadjuvant immunotherapy and chemotherapy.","volume":"11","author":"Cui","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"R7-20260923","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3892\/ol.2024.14586","article-title":"Misdiagnosis of severe and atypical oxaliplatin\u2011related hypersensitivity reaction following chemotherapy combined with PD\u20111 inhibitor: a case report and literature review.","volume":"28","author":"Sun","year":"2024","journal-title":"Oncol Lett"},{"key":"R8-20260923","doi-asserted-by":"crossref","first-page":"112542","DOI":"10.1016\/j.biopha.2021.112542","article-title":"Traditional Chinese medicine for precancerous lesions of gastric cancer: a review.","volume":"146","author":"Xu","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"R9-20260923","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial.","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"R10-20260923","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13020-019-0227-z","article-title":"Rapid discovery of chemical constituents and absorbed components in rat serum after oral administration of Fuzi-Lizhong pill based on high-throughput HPLC-Q-TOF\/MS analysis.","volume":"14","author":"Zhang","year":"2019","journal-title":"Chin Med"},{"key":"R11-20260923","doi-asserted-by":"crossref","first-page":"bbad518","DOI":"10.1093\/bib\/bbad518","article-title":"Network pharmacology: towards the artificial intelligence-based precision traditional Chinese medicine.","volume":"25","author":"Zhang","year":"2023","journal-title":"Brief Bioinform"},{"key":"R12-20260923","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cac2.12516","article-title":"The Chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023.","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"R13-20260923","first-page":"93","article-title":"The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging.","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R14-20260923","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","article-title":"Gastric cancer treatment: recent progress and future perspectives.","volume":"16","author":"Guan","year":"2023","journal-title":"J Hematol Oncol"},{"key":"R15-20260923","doi-asserted-by":"crossref","first-page":"116310","DOI":"10.1016\/j.biopha.2024.116310","article-title":"Deciphering drug resistance in gastric cancer: potential mechanisms and future perspectives.","volume":"173","author":"Liu","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"R16-20260923","doi-asserted-by":"crossref","first-page":"12385","DOI":"10.2147\/CMAR.S274599","article-title":"Multidrug resistance of gastric cancer: the mechanisms and Chinese medicine reversal agents.","volume":"12","author":"Huang","year":"2020","journal-title":"Cancer Manag Res"},{"key":"R17-20260923","doi-asserted-by":"crossref","first-page":"155169","DOI":"10.1016\/j.phymed.2023.155169","article-title":"Compound-composed Chinese medicine of Huachansu triggers apoptosis of gastric cancer cells through increase of reactive oxygen species levels and suppression of proteasome activities.","volume":"123","author":"Deng","year":"2024","journal-title":"Phytomedicine"},{"key":"R18-20260923","first-page":"1670014","article-title":"Action mechanism underlying improvement effect of Fuzi Lizhong decoction on nonalcoholic fatty liver disease: a study based on network pharmacology and molecular docking.","volume":"2022","author":"Luo","year":"2022","journal-title":"Evid Based Complement Alternat Med"},{"key":"R19-20260923","doi-asserted-by":"crossref","first-page":"3291853","DOI":"10.1155\/2020\/3291853","article-title":"Transcriptomic analysis of Fuzi Lizhong decoction for the treatment of stomach ulcers.","volume":"2020","author":"Xin","year":"2020","journal-title":"Evid Based Complement Alternat Med"},{"key":"R20-20260923","doi-asserted-by":"crossref","first-page":"153883","DOI":"10.1016\/j.phymed.2021.153883","article-title":"Ginsenoside Rd: a promising natural neuroprotective agent.","volume":"95","author":"Chen","year":"2022","journal-title":"Phytomedicine"},{"key":"R21-20260923","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10620-019-05771-8","article-title":"miR-146b regulates cell proliferation and apoptosis in gastric cancer by targeting PTP1B.","volume":"65","author":"Xu","year":"2020","journal-title":"Dig Dis Sci"},{"key":"R22-20260923","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41392-022-01190-w","article-title":"Signaling pathways and therapeutic interventions in gastric cancer.","volume":"7","author":"Lei","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"R23-20260923","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/cells10010099","article-title":"Estrogen and glycemic homeostasis: the fundamental role of nuclear estrogen receptors ESR1\/ESR2 in glucose transporter GLUT4 regulation.","volume":"10","author":"Gregorio","year":"2021","journal-title":"Cells"},{"key":"R24-20260923","doi-asserted-by":"crossref","first-page":"317452","DOI":"10.1155\/2010\/317452","article-title":"Estrogen receptor signaling and its relationship to cytokines in systemic lupus erythematosus.","volume":"2010","author":"Kassi","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"R25-20260923","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","article-title":"IL-6 in inflammation, autoimmunity and cancer.","volume":"33","author":"Hirano","year":"2021","journal-title":"Int Immunol"},{"key":"R26-20260923","doi-asserted-by":"crossref","first-page":"bbae466","DOI":"10.1093\/bib\/bbae466","article-title":"Novel systems biology experimental pipeline reveals matairesinol\u2019s antimetastatic potential in prostate cancer: an integrated approach of network pharmacology, bioinformatics, and experimental validation.","volume":"25","author":"Rajadnya","year":"2024","journal-title":"Brief Bioinform"},{"key":"R27-20260923","doi-asserted-by":"crossref","first-page":"103732","DOI":"10.1016\/j.fbio.2024.103732","article-title":"From dietary lignans to cancer therapy: integrative systems analysis of enterolactone\u2019s molecular targets and signaling pathways in combatting cancer stem cells in triple-negative breast cancer.","volume":"58","author":"Mahajan","year":"2024","journal-title":"Food Biosci"},{"key":"R28-20260923","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12943-024-02084-x","article-title":"The role of microRNAs in the gastric cancer tumor microenvironment.","volume":"23","author":"Yu","year":"2024","journal-title":"Mol Cancer"},{"key":"R29-20260923","first-page":"278","article-title":"miR-22-3p suppresses cell proliferation and migration of gastric cancer by targeting ENO1.","volume":"29","author":"Qiao","year":"2023","journal-title":"Altern Ther Health Med"},{"key":"R30-20260923","doi-asserted-by":"crossref","first-page":"708501","DOI":"10.3389\/fonc.2021.708501","article-title":"The LncRNA MIR503HG\/miR-224-5p\/TUSC3 signaling cascade suppresses gastric cancer development via modulating ATF6 branch of unfolded protein response.","volume":"11","author":"Lin","year":"2021","journal-title":"Front Oncol"},{"key":"R31-20260923","doi-asserted-by":"crossref","first-page":"e691","DOI":"10.1002\/ctm2.691","article-title":"Role of lncSLCO1C1 in gastric cancer progression and resistance to oxaliplatin therapy.","volume":"12","author":"Xiao","year":"2022","journal-title":"Clin Transl Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000044262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:00:56Z","timestamp":1790186456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000044262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":31,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044262","relation":{},"ISSN":["1536-5964","0025-7974"],"issn-type":[{"value":"1536-5964","type":"electronic"},{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"assertion":[{"value":"2025-06-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}